Results 91 to 100 of about 80,955 (206)

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer

, 2016
Recent preclinical studies revealed the efficacy of combined use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib in breast and prostate cancers. The current study investigated the effect of such drug combination on ovarian cancer.
Liu, Pixu, Bian, Xing, Wang, Dong, Roberts, Thomas, Jiang, Nan, Zhao, Jean, Zhang, Yuan, Wang, Min, Cheng, Hailing, Wang, Xiaoqing   +9 more
core   +1 more source

Co-Inhibition of PARP and STAT3 as a Promising Approach for Triple-Negative Breast Cancer

Biomolecules
Triple-negative breast cancer (TNBC) is a highly aggressive subtype known for its rapid metastatic potential. Despite its severity, treatment options for TNBC remain limited.
Changyou Shi, Li Pan, Satomi Amano, Mei-Yi Wu, Chenglong Li, Jiayuh Lin   +5 more
doaj   +1 more source

Roles of VRK3 in regulation of PARP1 stability and PARP inhibitor sensitivity

, 2018
Poly(ADP-ribose) polymerase 1 (PARP1) is one of the most critical protein in DNA repair response and is highly expressed in breast and ovarian cancer cell.
KIM, KYONG TAI, HAN, SEUNG HYUN
core  

Synergistic effects of combining PARP inhibitor (AZD2281) and ATR inhibitor (AZD6738) in Ewing Sarcoma cell lines [PDF]

, 2018
Ewing Sarcoma (ES) is an aggressive pediatric solid tumor. Even though overall-survival for localized patients is approximately 70%, the overall-survival for high risk ES patients has not improved in the last 20 years.
Meyer, Stephanie C.
core  

Effect of PARP inhibitor on Bcl-2, Bax and t-Bid protein levels in transplanted and control kidney samples.

, 2013
(A) Effects of PARP inhibitor on the Bcl-2, Bax and t-Bid protein levels in control and transplanted kidneys determined using immunoblotting with protein-specific primary antibodies. Actin was used as loading control.
Peter Degrell (318151), Istvan Wittmann (492217), Aliz Szabo (492215), Karoly Kalmar-Nagy (492214), Balazs Sumegi (81498), Ferenc Gallyas Jr (492218), Katalin Sumegi (492216)   +6 more
core   +1 more source

PARP inhibitors for prostate cancer

Seminars in Oncology
Poly(ADP-ribose) polymerase (PARP) inhibitors have transformed the treatment landscape for patients with metastatic castration-resistant prostate cancer (mCRPC) and alterations in DNA damage response genes. This has also led to widespread use of genomic testing in all patients with mCRPC.
Ossian Longoria, Nick Beije, Johann S. de Bono   +2 more
openaire   +2 more sources

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

, 2018
Accurately identifying patients with high-grade serous ovarian carcinoma (HGSOC) who respond to poly(ADP-ribose) polymerase inhibitor (PARPi) therapy is of great clinical importance.
Ho, GY, Nesic, K, Kondrashova, O, Heong, V, Zapparoli, GV, Hadley, A, Topp, M, Pearson, RB, Harrell, MI, Boehm, E, Holian, R, Hung, J, Lieschke, E, Sanij, E, et al.   +14 more
core   +1 more source

Targeting Latent HIV Reservoirs: Effectiveness of Combination Therapy with HDAC and PARP Inhibitors

Viruses
The “Kick and Kill” strategy, which aims to reactivate latent HIV reservoirs and facilitate the clearance of reactivated HIV-infected cells, has yet to achieve a functional cure due to the limited efficacy of current latency reversal agents.
Hasset Tibebe, Dacia Marquez, Aidan McGraw, Sophia Gagliardi, Cailyn Sullivan, Grace Hillmer, Kedhar Narayan, Coco Izumi, Adleigh Keating, Taisuke Izumi   +9 more
doaj   +1 more source

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer

, 2015
Metaplastic breast carcinoma (MBC) is a rare histological breast cancer subtype characterized by mesenchymal elements and poor clinical outcome. A large fraction of MBCs harbor defects in breast cancer 1 (BRCA1).
Pritchard, Colin, Berns, Anton, Rottenberg, S., de Korte-Grimmerink, Renske, Rottenberg, Sven, Gogola, Ewa, Drenth, A.P., Huijbers, Ivo J, Gogola, E., Pritchard, C., Braumuller, T.M., Henneman, Linda, Jonkers, J., Drenth, Anne Paulien, Miltenburg, M.H. van, Henneman, L., Jaspers, Janneke E, Jaspers, J.E., Ali, R. bin, Berns, A., Schlicker, A., Szuhai, Karoly, Bin Ali, Rahmen, Michalak, E.M., van Miltenburg, Martine H, Jonkers, Jos, Huijbers, I.J., Braumuller, Tanya M, Schlicker, Andreas, Szuhai, K., Korte-Grimmerink, R. de, Michalak, Ewa M   +31 more
core   +1 more source

Temozolomide enhances PARP inhibitor sensitivity in multiple tumour types.

, 2015
List of cell lines screened against a combination of olaparib and temozolomide. Whether enhancement of PARP inhibitor sensitivity with temozolomide is observed (✔) or not (✖) is indicated.
Jon Travers (818670), Tatiana Mironenko (818674), Laura Richardson (818675), Irina Pshenichnaya (818671), Cyril H. Benes (408440), Michael R. Stratton (561654), Sonja J. Gill (818669), Syd Barthorpe (818673), Fiona A. Kogera (818672), Ultan McDermott (213251), Stephen P. Jackson (119194), Mathew J. Garnett (811548)   +11 more
core   +1 more source